Glutamine

Area of Science:

• Clinical Nutrition
• Critical Care Medicine
• Pharmacology

Background:

• Glutamine (GLN) is recognized as a crucial pharmaconutrient supporting the body's response to stress and injury.
• GLN offers protective effects through mechanisms like direct tissue protection, inflammation attenuation, and metabolic function preservation.

Purpose of the Study:

• To evaluate Glutamine (GLN) as a pharmacologic intervention for preventing or treating multiple organ dysfunction syndrome (MODS) in intensive care unit (ICU) patients.
• To synthesize current clinical data on GLN's efficacy and identify optimal administration parameters for critically ill populations.

Main Methods:

• Review and synthesis of existing clinical data on Glutamine (GLN) administration in critically ill patients.
• Analysis of patient outcomes related to varying GLN dosages, durations, and routes of administration.

Main Results:

• Clinical data indicate Glutamine (GLN) can be a life-saving intervention in specific critically ill patient groups.
• Greatest benefit observed with GLN doses exceeding 0.35 g/kg/day, potentially optimal at 0.5 g/kg/day.
• Prolonged administration (over 5 days, ideally entire ICU/hospital stay) and early administration (within 24-48 hours of ICU admission) may enhance outcomes.

Conclusions:

• Glutamine (GLN) is a valuable therapeutic agent for critically ill patients, particularly those with sepsis or injury.
• Optimizing GLN therapy involves higher doses, extended duration, and early administration via enteral or parenteral routes.
• Ongoing trials aim to further define the most effective strategies for GLN administration in the ICU setting.